Lyratrutide is evaluated as a drug that has evolved one step further than the existing GLP-1 family obesity drug
These symptoms are typically mild to moderate and tend to decrease over time as the body adjusts to the medication
However, these medications are available in combination with metformin or other antihyperglycemic agents, which may provide the advantage of decreased pill burden for patients with uncontrolled diabetes
Clinical data from SURMOUNT-1 supports the staircase approach, as it is the protocol that produced the headline weight loss numbers
Recently, another investigation appearing in the journal Retina evaluated how the popular drug impacts the risk of AMD development and progression, specifically among patients with type 2 diabetes
Both medications help with significant weight loss, though they work slightly differently